Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon

Palmer Masumbe Netongo; Marie Christine Magne Nzuno; Severin Donald Kamdem; Desire Keptcheu; Armel Herve Nwabo Kamdje; Irene Ane Anyangwe

doi:doi:10.11648/j.ejcbs.20220803.14

Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon

Palmer Masumbe Netongo, Marie Christine Magne Nzuno, Severin Donald Kamdem, Desire Keptcheu, Armel Herve Nwabo Kamdje, Irene Ane Anyangwe

Published in European Journal of Clinical and Biomedical Sciences (Volume 8, Issue 3)

Received: 23 May 2022 Accepted: 20 June 2022 Published: 30 June 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.

Published in	European Journal of Clinical and Biomedical Sciences (Volume 8, Issue 3)
DOI	10.11648/j.ejcbs.20220803.14
Page(s)	49-54
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Interleukin-6 ELISA, Early Diagnosis, Neonatal Sepsis, Feasibility

References

[1]	Ndombo, P. K., Ekei, Q. M., Tochie, J. N., Temgoua, M. N., Angong, F. T. E., Ntock, F. N., and Mbuagbaw, L. (2017) A cohort analysis of neonatal hospital mortality rate and predictors of neonatal mortality in a sub-urban hospital of Cameroon, Italian journal of pediatrics 43, 1-8.
[2]	Bhatti, M., Chu, A., Hageman, J. R., Schreiber, M., and Alexander, K. (2012) Future directions in the evaluation and management of neonatal sepsis, NeoReviews 13, e103-e110.
[3]	Kocabas, E., Sarikcioglu, A., Aksaray, N., Seydaoglu, G., Seyhun, Y., and Yaman, A. (2007) Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis, Turkish Journal of Pediatrics 49, 7.
[4]	Resch, B., Hofer, N., and Müller, W. (2012) Challenges in the diagnosis of sepsis of the neonate, Reasearch for neonatal infectious diseases and epidemiology 2012, 233-245.
[5]	Lichtenstern, C., Brenner, T., Bardenheuer, H. J., and Weigand, M. A. (2012) Predictors of survival in sepsis: what is the best inflammatory marker to measure?, Current opinion in infectious diseases 25, 328-336.
[6]	Herzum, I., and Renz, H. (2008) Inflammatory markers in SIRS, sepsis and septic shock, Current medicinal chemistry 15, 581-587.
[7]	Prashant, A., Vishwanath, P., Kulkarni, P., Sathya Narayana, P., Gowdara, V., Nataraj, S. M., and Nagaraj, R. (2013) Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis–a case control study, PloS one 8, e68426.
[8]	Reinhart, K., Meisner, M., and Brunkhorst, F. M. (2006) Markers for sepsis diagnosis: what is useful?, Critical care clinics 22, 503-519.
[9]	Bowen, D. J., Kreuter, M., Spring, B., Cofta-Woerpel, L., Linnan, L., Weiner, D., Bakken, S., Kaplan, C. P., Squiers, L., and Fabrizio, C. (2009) How we design feasibility studies, American journal of preventive medicine 36, 452-457.
[10]	Wu, Y., Shen, J., Zhou, Q., Zhao, H., Liu, L., and Liu, X. (2016) Interleukin-6 and interleukin-8 in diagnosing neonatal septicemia, Journal of Biological Regulators and Homeostatic Agents 30, 1107-1113.
[11]	Küster, H., Weiss, M., Willeitner, A. E., Detlefsen, S., Jeremias, I., Zbojan, J., Geiger, R., Lipowsky, G., and Simbruner, G. (1998) Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation, The Lancet 352, 1271-1277.
[12]	Silveira, R., and Procianoy, R. (1999) Evaluation of interleukin-6, tumour necrosis factor-α and interleukin-1β for early diagnosis of neonatal sepsis, Acta paediatrica 88, 647-650.
[13]	Buck, C., Bundschu, J., Bartmann, P., Pohlandt, F., and Gallati, H. (1994) Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection, Pediatrics 93, 54-58.
[14]	Mirzarahimi, M., Barak, M., Eslami, A., and Enteshari-Moghaddam, A. (2017) The role of interleukin-6 in the early diagnosis of sepsis in premature infants, Pediatric reports 9, 7305.
[15]	Yachie, A., Takano, N. U., Ohta, K., Uehara, T., Fujita, S., Miyawaki, T., and Taniguchi, N. (1992) Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens, Infection and immunity 60, 749-753.
[16]	Khassawneh, M., Hayajneh, W., Kofahi, H., Khader, Y., Amarin, Z., and Daoud, A. (2007) Diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6 and immunoglobulin M, Scandinavian Journal of Immunology 65, 171-175.
[17]	Franz, A. R., Steinbach, G., Kron, M., and Pohlandt, F. (1999) Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections, Pediatrics 104, 447-453.
[18]	De Bont, E., Martens, A., Van Raan, J., Samson, G., Fetter, W., Okken, A., De Leij, L., and Kimpen, J. (1994) Diagnostic value of plasma levels of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) in newborns with sepsis, Acta paediatrica 83, 696-699.
[19]	Messer, J., Eyer, D., Donato, L., Gallati, H., Matis, J., and Simeoni, U. (1996) Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection, The Journal of pediatrics 129, 574-580.
[20]	Døllner, H., Vatten, L., and Austgulen, R. (2001) Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules, Journal of clinical epidemiology 54, 1251-1257.
[21]	Sonawane, V. B., Mehkarkar, N. S., Jadhav, P. B., Gaikwad, S. U., and Kadam, N. N. (2015) Study of interleukin-6 levels in early diagnosis of neonatal sepsis.
[22]	(2020) ASTMH Membership Directory, Am J Trop Med Hyg 102, 21-233.
[23]	Mardini, V., Rohde, L. A., Ceresér, K. M. M., Gubert, C. d. M., Silva, E. G. d., Xavier, F., Parcianello, R., Röhsig, L. M., Pechansky, F., and Pianca, T. G. (2016) IL-6 and IL-10 levels in the umbilical cord blood of newborns with a history of crack/cocaine exposure in utero: a comparative study, Trends in psychiatry and psychotherapy 38, 40-49.
[24]	Chauhan, N., Tiwari, S., and Jain, U. (2017) Potential biomarkers for effective screening of neonatal sepsis infections: an overview, Microbial pathogenesis 107, 234-242.
[25]	Cernada, M., Badía, N., Modesto, V., Alonso, R., Mejías, A., Golombek, S., and Vento, M. (2012) Cord blood interleukin-6 as a predictor of early-onset neonatal sepsis, Acta paediatrica 101, e203-e207.
[26]	Behrman, R., Kliegman, R., and Jenson, H. (2000) Jaundice and hyperbilirubinemia in the newborn, Nelson Textbook of Pediatrics 1, 493-499.
[27]	Chiesa, C., Panero, A., Osborn, J. F., Simonetti, A. F., and Pacifico, L. (2004) Diagnosis of neonatal sepsis: a clinical and laboratory challenge, Clinical chemistry 50, 279-287.
[28]	Ng, P. (2004) Diagnostic markers of infection in neonates, Archives of Disease in Childhood-Fetal and Neonatal Edition 89, F229-F235.
[29]	Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., and Xu, H. (2020) Positive RT-PCR test results in patients recovered from COVID-19, Jama 323, 1502-1503.
[30]	Aziz, M., Fatima, R., and Assaly, R. (2020) Elevated interleukin-6 and severe COVID-19: a meta-analysis, Journal of medical virology.
[31]	Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J, Li F. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated with Drastically Elevated Interleukin 6 Level in Critically Ill Patients with Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 5; 71 (8): 1937-1942.
[32]	Ulhaq, Z. S. and G. V. Soraya, Interleukin-6 as a potential biomarker of COVID-19 progression. Medecine et maladies infectieuses, 2020. 50 (4): p. 382.
[33]	Singh, B., et al., Interleukin-6 expression in cord blood of patients with clinical chorioamnionitis. Pediatric research, 1996. 39 (6): p. 976-979.

Cite This Article

Plain Text BibTeX RIS

APA Style

Palmer Masumbe Netongo, Marie Christine Magne Nzuno, Severin Donald Kamdem, Desire Keptcheu, Armel Herve Nwabo Kamdje, et al. (2022). Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. European Journal of Clinical and Biomedical Sciences, 8(3), 49-54. https://doi.org/10.11648/j.ejcbs.20220803.14

Copy | Download

ACS Style

Palmer Masumbe Netongo; Marie Christine Magne Nzuno; Severin Donald Kamdem; Desire Keptcheu; Armel Herve Nwabo Kamdje, et al. Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. Eur. J. Clin. Biomed. Sci. 2022, 8(3), 49-54. doi: 10.11648/j.ejcbs.20220803.14

Copy | Download

AMA Style

Palmer Masumbe Netongo, Marie Christine Magne Nzuno, Severin Donald Kamdem, Desire Keptcheu, Armel Herve Nwabo Kamdje, et al. Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. Eur J Clin Biomed Sci. 2022;8(3):49-54. doi: 10.11648/j.ejcbs.20220803.14

Copy | Download

@article{10.11648/j.ejcbs.20220803.14,
  author = {Palmer Masumbe Netongo and Marie Christine Magne Nzuno and Severin Donald Kamdem and Desire Keptcheu and Armel Herve Nwabo Kamdje and Irene Ane Anyangwe},
  title = {Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon},
  journal = {European Journal of Clinical and Biomedical Sciences},
  volume = {8},
  number = {3},
  pages = {49-54},
  doi = {10.11648/j.ejcbs.20220803.14},
  url = {https://doi.org/10.11648/j.ejcbs.20220803.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20220803.14},
  abstract = {Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon
AU  - Palmer Masumbe Netongo
AU  - Marie Christine Magne Nzuno
AU  - Severin Donald Kamdem
AU  - Desire Keptcheu
AU  - Armel Herve Nwabo Kamdje
AU  - Irene Ane Anyangwe
Y1  - 2022/06/30
PY  - 2022
N1  - https://doi.org/10.11648/j.ejcbs.20220803.14
DO  - 10.11648/j.ejcbs.20220803.14
T2  - European Journal of Clinical and Biomedical Sciences
JF  - European Journal of Clinical and Biomedical Sciences
JO  - European Journal of Clinical and Biomedical Sciences
SP  - 49
EP  - 54
PB  - Science Publishing Group
SN  - 2575-5005
UR  - https://doi.org/10.11648/j.ejcbs.20220803.14
AB  - Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.
VL  - 8
IS  - 3
ER  -

Copy | Download

Author Information

Palmer Masumbe Netongo

Molecular Diagnostics Research Group, The Biotechnology Centre-University of Yaounde I, Yaounde, Cameroon
Marie Christine Magne Nzuno

Molecular Diagnostics Research Group, The Biotechnology Centre-University of Yaounde I, Yaounde, Cameroon
Severin Donald Kamdem

Molecular Diagnostics Research Group, The Biotechnology Centre-University of Yaounde I, Yaounde, Cameroon
Desire Keptcheu

Laboratory Department, Bafoussam Regional Hospital, Bafoussam, Cameroon
Armel Herve Nwabo Kamdje

Department of Physiology and Biochemistry, Faculty of Medicine, University of Ngaoundere, Ngaoundere, Cameroon
Irene Ane Anyangwe

School of Science - Biology Program, Navajo Technical University, Crownpoint, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Palmer Masumbe Netongo, Marie Christine Magne Nzuno, Severin Donald Kamdem, Desire Keptcheu, Armel Herve Nwabo Kamdje, et al. (2022). Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. European Journal of Clinical and Biomedical Sciences, 8(3), 49-54. https://doi.org/10.11648/j.ejcbs.20220803.14

Copy | Download

ACS Style

Palmer Masumbe Netongo; Marie Christine Magne Nzuno; Severin Donald Kamdem; Desire Keptcheu; Armel Herve Nwabo Kamdje, et al. Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. Eur. J. Clin. Biomed. Sci. 2022, 8(3), 49-54. doi: 10.11648/j.ejcbs.20220803.14

Copy | Download

AMA Style

Palmer Masumbe Netongo, Marie Christine Magne Nzuno, Severin Donald Kamdem, Desire Keptcheu, Armel Herve Nwabo Kamdje, et al. Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon. Eur J Clin Biomed Sci. 2022;8(3):49-54. doi: 10.11648/j.ejcbs.20220803.14

Copy | Download

@article{10.11648/j.ejcbs.20220803.14,
  author = {Palmer Masumbe Netongo and Marie Christine Magne Nzuno and Severin Donald Kamdem and Desire Keptcheu and Armel Herve Nwabo Kamdje and Irene Ane Anyangwe},
  title = {Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon},
  journal = {European Journal of Clinical and Biomedical Sciences},
  volume = {8},
  number = {3},
  pages = {49-54},
  doi = {10.11648/j.ejcbs.20220803.14},
  url = {https://doi.org/10.11648/j.ejcbs.20220803.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20220803.14},
  abstract = {Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Interleukin-6 ELISA in the Early Diagnosis of Neonatal Sepsis: Feasibility Within a Poor Setting in Bafoussam, Cameroon
AU  - Palmer Masumbe Netongo
AU  - Marie Christine Magne Nzuno
AU  - Severin Donald Kamdem
AU  - Desire Keptcheu
AU  - Armel Herve Nwabo Kamdje
AU  - Irene Ane Anyangwe
Y1  - 2022/06/30
PY  - 2022
N1  - https://doi.org/10.11648/j.ejcbs.20220803.14
DO  - 10.11648/j.ejcbs.20220803.14
T2  - European Journal of Clinical and Biomedical Sciences
JF  - European Journal of Clinical and Biomedical Sciences
JO  - European Journal of Clinical and Biomedical Sciences
SP  - 49
EP  - 54
PB  - Science Publishing Group
SN  - 2575-5005
UR  - https://doi.org/10.11648/j.ejcbs.20220803.14
AB  - Introduction: Neonatal sepsis is a leading cause of mortality in Cameroon. Diagnosis still relies heavily on the detection of C reactive protein (CRP) levels, whereas other biomarkers like interleukin 6 (IL-6), could improve the early diagnosis of neonatal sepsis in comparison to CRP. This study aimed to assess the efficacy and feasibility of IL-6 ELISA as an early diagnostic tool within a Cameroonian context with the hope of its applicability in other poor income settings and in other diseases like COVID-19. Methods: We enrolled thirty-two (32) neonates equally distributed between a septic group (including infants with risk factors and clinical signs of sepsis) and a control group (infants without clinical signs of infections) in the study. We performed Full Blood Count, C-reactive protein and IL-6 ELISA on all blood samples. Thirty-five (35) medical personnel were interviewed in order to assess acceptability, practicality (cost and duration) and a limited-efficacy of IL-6 ELISA testing at the Bafoussam regional Hospital, Cameroon. Results: The mean age of participants was 2.81 days. IL-6 ELSIA showed a sensitivity, specificity, positive predictive value and negative predictive value of 56.20%, 100%, 100% and 69.56% respectively while CRP was reported to be highly specific (81.25%). Despite a longer testing time of IL-6 ELISA compared to CRP (p = 0.0385), the IL-6 was acceptable (p = 0.008), affordable (p = 0.006) and could be promising for use within this poor setting. Conclusion: Though we did not see a strong correlation between its levels and the apparition of disease, IL-6 ELISA testing was feasible as a highly specific marker for an early diagnosis neonatal sepsis in Bafoussam, and could acceptably be used as an early diagnostic marker for other diseases like COVID-19 within that context.
VL  - 8
IS  - 3
ER  -

Copy | Download